Hikma Pharmaceuticals Stock Forecast, Price & News

+1.00 (+3.13 %)
(As of 04/9/2021 08:27 PM ET)
Today's Range
Now: $33.00
50-Day Range
MA: $32.01
52-Week Range
Now: $33.00
Volume100 shs
Average Volume766 shs
Market Capitalization$8.00 billion
P/E Ratio22.00
Dividend Yield0.48%
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Hikma Pharmaceuticals logo

Industry, Sector and Symbol

Industry Private households
Year FoundedN/A



Sales & Book Value

Annual Sales$2.21 billion
Cash Flow$1.71 per share
Book Value$8.79 per share



Market Cap$8.00 billion
Next Earnings DateN/A
OptionableNot Optionable


MGE Energy to Present at EEI Financial Conference
November 9, 2020 |  finance.yahoo.com
MGE Energy Issues Second-Quarter Financial Update
August 10, 2020 |  finance.yahoo.com
Hikma Pharmaceuticals beats on revenue
August 7, 2020 |  seekingalpha.com
Hikma Pharma pretax profit climbs 21%
August 7, 2020 |  msn.com
MGE Energy Issues June 2020 'Interim Report'
June 15, 2020 |  finance.yahoo.com
Hikma receives FDA approval for its generic Vascepa®
May 22, 2020 |  markets.businessinsider.com
Is Amarin Stock a Buy?
May 19, 2020 |  finance.yahoo.com
See More Headlines


Overall MarketRank

1.27 out of 5 stars

Medical Sector

840th out of 2,016 stocks

Private Households Industry

60th out of 378 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
+1.00 (+3.13 %)
(As of 04/9/2021 08:27 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HKMPF News and Ratings via Email

Sign-up to receive the latest news and ratings for HKMPF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions

Is Hikma Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Hikma Pharmaceuticals stock.
View analyst ratings for Hikma Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Hikma Pharmaceuticals?

Wall Street analysts have given Hikma Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hikma Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Hikma Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Hikma Pharmaceuticals' stock was trading at $24.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HKMPF stock has increased by 34.7% and is now trading at $33.00.
View which stocks have been most impacted by COVID-19

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a Semi-Annual dividend on Thursday, February 25th. Investors of record on Friday, March 19th will be given a dividend of $0.34 per share on Monday, April 26th. The ex-dividend date of this dividend is Thursday, March 18th.
View Hikma Pharmaceuticals' dividend history

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and currently has a dividend yield of 0.48%. The dividend payout ratio of Hikma Pharmaceuticals is 10.67%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Hikma Pharmaceuticals will have a dividend payout ratio of 8.84% next year. This indicates that Hikma Pharmaceuticals will be able to sustain or increase its dividend.
View Hikma Pharmaceuticals' dividend history.

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 64, Pay $3.01M)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 52, Pay $3.72M)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 63, Pay $2.16M)
  • Mr. Khalid Waleed Hosny Al Nabilsi, Chief Financial Officer (Age 49)
  • Ms. Henriette Nielsen, Exec. VP of Bus. Operations
  • Dr. Shahin Fesharaki, Chief Scientific Officer
  • Mr. Hussein Arkhagha, Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan, Exec. VP of Corp. Devel. and M&A (Age 56)
  • Ms. Susan Ringdal, Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi, Exec. VP of Organisational Devel.

Who are some of Hikma Pharmaceuticals' key competitors?

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPF stock can currently be purchased for approximately $33.00.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals has a market capitalization of $8.00 billion and generates $2.21 billion in revenue each year. The company earns $486 million in net income (profit) each year or $1.50 on an earnings per share basis.

How many employees does Hikma Pharmaceuticals have?

Hikma Pharmaceuticals employs 8,600 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

Where are Hikma Pharmaceuticals' headquarters?

Hikma Pharmaceuticals is headquartered at 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 44-20-7399-2760 or via email at [email protected]

This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.